Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 3Stomach Neoplasms 2Sarcoma 2Recurrence 2Melanoma 2Uterine Cervical Neoplasms 1Testicular Germ Cell Tumor 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma 1Liposarcoma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma of Lung 1

Interventions

tislelizumab 1milademetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Testicular Germ Cell Tumor × milademetan × Clear all
NCT05012397 2024-10-17

Milademetan in Advanced/Metastatic Solid Tumors

Rain Oncology Inc

Phase 2 Terminated
40 enrolled 13 charts
DermatologicEndocrineGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡